Company Overview
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.
Recent News
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
Stock Overview
Symbol
SCYX
Exchange
Nasdaq
Market Cap
35.86m
Last Price
$0.92
52-Week Range
$0.72 - $3.07
04/21/2025 08:00 PM EDT